Novo Nordisk is a global healthcare company with 95 years of innovation and leadership in diabetes care. This heritage has given us experience and capabilities that also enable us to help people defeat obesity, haemophilia, growth disorders and other serious chronic diseases. Headquartered in Denmark, Novo Nordisk employs approximately 43200 employees in 80 countries, and markets its products in more than 170 countries.
COVID-19 and medicine supply
During the COVID-19 pandemic, our key priority is to safeguard the health of our employees and the continued supply of our lifesaving medicines to patients. Currently we are not experiencing any constraints with our production.
We are aware that health authorities and pharmacies are doing their best to ensure the availability of insulin for those who need it during the coronavirus pandemic, and we can assure you that our current stock levels are normal. It is important for us that you are informed and reassured. As we continue to monitor the situation, we will share our updates.
If you have any questions or concerns, please contact us: Tel +852 2387 8555.
Learn more on www.novonordisk.com
Novo Nordisk Hong Kong Limited
Tel: +852 2387 8555
DKSH Hong Kong Limited
Tel: +852 2895 9668
Your information about complaints and side effects helps us ensure the safe use of our products. If you have experienced a complaint or a side effect to a Novo Nordisk product, we encourage you to also report this to Novo Nordisk.
Please e-mail: email@example.com
or call us on +852 2387 8555
If you or the person you are reporting on behalf of are currently suffering from severe side effects, you should contact your local doctor or other medical health professional before reporting the side effect.
All personal information reported in relation to a complaint or a side effect will be processed in accordance with applicable data protection legislation:
• Your report is used solely for the scientific evaluation of the medicine and product quality
• Side effects are filed in our global safety database and the data is regularly analysed for overall patterns
• Novo Nordisk may share reported complaints and side effects with health authorities as mandated by law. However, no personally identifiable details will be shared
• Novo Nordisk will retain the data as long as required by law